BofA Securities Upgrades Tandem Diabetes Care (TNDM) to Neutral

BofA Securities analyst Travis Steed upgraded Tandem Diabetes Care (NASDAQ: TNDM) from Underperform to Neutral with a price target of $30.00 (from $15.00).

The analyst commented: "We upgrade TNDM to Neutral and raise our PO to $30 (2x 2026 revenue) given we see TNDM becoming a more profitable company over the next two years. TNDM is moving more into the pharmacy channel and shifting more to a pay as you go business model. These changes should help TNDM's new starts along with the pipeline (Tobi at least incrementally more competitive than Mobi). TNDM is saying its leading indicator (new starts) will finally return to growth and TNDM sees accelerated revenue growth in 2027 and beyond. While there is some execution risk and deferred revenue, these changes could set TNDM up as a stronger, more profitable, company. The revenue per patient in the new model could double which means it takes fewer patients to achieve profitability. "

For an analyst ratings summary and ratings history on Tandem Diabetes Care click here. For more ratings news on Tandem Diabetes Care click here.

Shares of Tandem Diabetes Care closed at $18.52 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Aurora Spine settles patent dispute, secures $600K insider loan